Last month, Sheba officials ratified a memorandum of understanding with G42 Healthcare, a leading Abu Dhabi-based healthtech company specializing in artificial intelligence-based innovations.
The two sides will team up on collaborative projects aimed at introducing cutting-edge healthcare innovations in the UAE and Israel, focusing on AI-driven solutions connected to stem cell research programs, infrastructure building, as well as advances in cardiology, oncology, gynecology, diabetes, fertility, and other medical disciplines.
One of the key aspects of the collaboration involves leveraging the capabilities of G42 Healthcare’s Insights Research Organization and Solutions (IROS), the first UAE-based contract research organization (CRO).
Speaking during a signing ceremony in Abu Dhabi, Dr. Fahed Al Marzooqi, Chief Operating Officer of G42 Healthcare, expressed his eagerness to partner in “advancing scientific and ethical research, conducting clinical trials, and ensuring access to innovative life-changing treatments.”
Prof. Yitshak Kreiss: It’s a pleasure to partner with G42 Healthcare
Prof. Yitshak Kreiss, Sheba’s Director General, added: “In line with Sheba’s commitment to providing ‘hope without boundaries,’ improving care, and treating patients suffering from complex conditions, we are always on the lookout for impactful collaborations. It is, therefore, a pleasure to partner with G42 Healthcare to accelerate clinical research, enhance patient access to novel treatments and help improve patient outcomes with an emphasis on creating a better quality of life.”
Since the signing of the Abraham Accords in August 2020, Sheba has launched several therapeutic and research initiatives to build relations and collaborate with Gulf countries, including a partnership with Bahrain’s largest hospital on research initiatives and signing an MOU with the Department of Health in Abu Dhabi to develop improved healthcare services.